miR‐221 confers lapatinib resistance by negatively regulating p27(kip1) in HER2‐positive breast cancer

Development of acquired resistance to lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor, severely limits the duration of clinical response in advanced HER2‐driven breast cancer patients. Although the compensatory activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Huynh, Thanh Kieu, Huang, Chih‐Hao, Chen, Jhen‐Yu, Yao, Jin‐Han, Yang, Yi‐Shiang, Wei, Ya‐Ling, Chen, Hsiao‐Fan, Chen, Chia‐Hung, Tu, Chih‐Yen, Hsu, Yuan‐Man, Liu, Liang‐Chih, Huang, Wei‐Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486195/
https://www.ncbi.nlm.nih.gov/pubmed/34382727
http://dx.doi.org/10.1111/cas.15107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486195/
https://www.ncbi.nlm.nih.gov/pubmed/34382727
http://dx.doi.org/10.1111/cas.15107

Ejemplares similares